Related Experiment Video
Updated: May 5, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.0K
Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study
Stephan Miehlke1, Ahmed Madisch, Diana Karimi
1Medical Department I, Technical University Hospital, Dresden, Germany. stephan.miehlke@uniklinikum-dresden.de
Gastroenterology
|March 24, 2009
Summary
Budesonide effectively treats lymphocytic colitis, achieving high remission rates in a clinical trial. Relapses occurred but responded well to retreatment, indicating budesonide
Area of Science:
- Gastroenterology
- Clinical Pharmacology
Background:
- Lymphocytic colitis lacks established treatments, unlike collagenous colitis.
- Budesonide is a known effective treatment for collagenous colitis.
Purpose of the Study:
- To evaluate the efficacy of budesonide for treating lymphocytic colitis.
- To assess budesonide's impact on clinical and histological outcomes.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 42 patients with lymphocytic colitis.
- Patients received budesonide (9 mg/d) or placebo for 6 weeks, followed by open-label budesonide for non-responders.
- Clinical remission, histologic remission, and quality of life were assessed.
Main Results:
- 86% of budesonide recipients achieved clinical remission versus 48% of placebo recipients (P = .010).
- Histologic remission was significantly higher in the budesonide group (73% vs. 31%, P = .030).
- Relapses occurred in 44.1% of patients but responded to retreatment with budesonide.
Conclusions:
- Budesonide is an effective treatment for inducing clinical remission in lymphocytic colitis.
- Budesonide significantly improves histological findings in patients with lymphocytic colitis.
- Recurrent disease can be effectively managed with repeat budesonide therapy.
More Related Videos
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K